CY1113733T1 - Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων - Google Patents

Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων

Info

Publication number
CY1113733T1
CY1113733T1 CY20121101169T CY121101169T CY1113733T1 CY 1113733 T1 CY1113733 T1 CY 1113733T1 CY 20121101169 T CY20121101169 T CY 20121101169T CY 121101169 T CY121101169 T CY 121101169T CY 1113733 T1 CY1113733 T1 CY 1113733T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
kinolinonine
producers
compounds
inactivator
Prior art date
Application number
CY20121101169T
Other languages
Greek (el)
English (en)
Inventor
Olivier Lohse
Stéphanie Monnier
Jean-Louis Reber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1113733T1 publication Critical patent/CY1113733T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20121101169T 2006-06-30 2012-11-29 Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων CY1113733T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
EP07819899A EP2044025B1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY1113733T1 true CY1113733T1 (el) 2016-06-22

Family

ID=38610531

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20121101169T CY1113733T1 (el) 2006-06-30 2012-11-29 Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
CY2020038C CY2020038I2 (el) 2006-06-30 2020-11-26 Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
CY2020041C CY2020041I1 (el) 2006-06-30 2020-12-14 Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2020038C CY2020038I2 (el) 2006-06-30 2020-11-26 Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
CY2020041C CY2020041I1 (el) 2006-06-30 2020-12-14 Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων

Country Status (29)

Country Link
US (2) US8198450B2 (enExample)
EP (1) EP2044025B1 (enExample)
JP (1) JP5253392B2 (enExample)
KR (1) KR101402398B1 (enExample)
CN (1) CN101479245B (enExample)
AU (1) AU2007264946B2 (enExample)
BE (2) BE2020C550I2 (enExample)
BR (1) BRPI0713951B8 (enExample)
CA (1) CA2654801C (enExample)
CY (3) CY1113733T1 (enExample)
DK (1) DK2044025T3 (enExample)
ES (1) ES2396987T3 (enExample)
FI (2) FIC20200047I1 (enExample)
FR (2) FR20C1054I1 (enExample)
HR (1) HRP20121074T1 (enExample)
HU (2) HUS2000043I1 (enExample)
IL (1) IL195796A (enExample)
LT (2) LTC2044025I2 (enExample)
LU (2) LUC00185I2 (enExample)
MA (1) MA30540B1 (enExample)
MX (1) MX2008016542A (enExample)
MY (1) MY150468A (enExample)
NO (3) NO341709B1 (enExample)
NZ (1) NZ573292A (enExample)
PL (1) PL2044025T3 (enExample)
PT (1) PT2044025E (enExample)
SI (1) SI2044025T1 (enExample)
WO (1) WO2008000839A1 (enExample)
ZA (1) ZA200809948B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2452965T3 (es) 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法
WO2026027448A1 (en) 2024-07-29 2026-02-05 Inke, S.A. Micronization process of indacaterol acetate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc 2−アニリノ−3−メチル−6−(N−n−ブチル−N−シクロヘキシルアミノ)フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en) 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
ATE421322T1 (de) 2003-04-04 2009-02-15 Novartis Pharma Gmbh Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
CN101142217B (zh) 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
KR101402398B1 (ko) 2014-06-03
CY2020038I1 (el) 2021-03-12
CY2020038I2 (el) 2021-03-12
CY2020041I2 (el) 2021-03-12
SI2044025T1 (sl) 2013-01-31
PT2044025E (pt) 2012-12-17
MX2008016542A (es) 2009-01-19
LTPA2020535I1 (lt) 2020-12-28
ES2396987T3 (es) 2013-03-01
FIC20200050I1 (fi) 2020-12-16
FR20C1063I1 (fr) 2021-01-22
IL195796A (en) 2016-03-31
FR20C1054I1 (fr) 2020-12-25
US20090325912A1 (en) 2009-12-31
JP2009541455A (ja) 2009-11-26
PL2044025T3 (pl) 2013-02-28
AU2007264946A1 (en) 2008-01-03
CN101479245A (zh) 2009-07-08
CA2654801A1 (en) 2008-01-03
EP2044025A1 (en) 2009-04-08
NO2020044I1 (no) 2020-12-07
CA2654801C (en) 2014-08-19
MA30540B1 (fr) 2009-06-01
US8198450B2 (en) 2012-06-12
LUC00188I2 (enExample) 2024-07-01
LUC00185I2 (enExample) 2024-07-01
NZ573292A (en) 2011-03-31
IL195796A0 (en) 2009-09-01
HUS2000043I1 (hu) 2020-12-28
DK2044025T3 (da) 2013-01-14
JP5253392B2 (ja) 2013-07-31
ZA200809948B (en) 2009-05-25
BE2020C552I2 (enExample) 2026-07-08
HUS2000053I1 (hu) 2020-12-28
KR20090023651A (ko) 2009-03-05
BE2020C550I2 (enExample) 2026-07-08
AU2007264946B2 (en) 2011-01-20
WO2008000839A1 (en) 2008-01-03
EP2044025B1 (en) 2012-10-03
MY150468A (en) 2014-01-30
NO20090312L (no) 2009-01-28
NO341709B1 (no) 2018-01-02
US20120316142A1 (en) 2012-12-13
BRPI0713951A2 (pt) 2012-12-04
NO2020041I1 (no) 2020-11-23
BRPI0713951B8 (pt) 2021-05-25
FIC20200047I1 (fi) 2020-11-27
LTC2044025I2 (lt) 2022-10-10
CN101479245B (zh) 2013-05-22
LTPA2020538I1 (lt) 2021-01-11
BRPI0713951B1 (pt) 2019-08-13
CY2020041I1 (el) 2021-03-12
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31

Similar Documents

Publication Publication Date Title
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
CY1122542T1 (el) Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CY1108894T1 (el) Νεα παραγωγα βενζιμιδαζολης
TW200613243A (en) Novel compounds
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
SE0302811D0 (sv) Novel compounds
SE0401762D0 (sv) Novel compounds
CY1107426T1 (el) Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
MX2010006421A (es) Compuestos organicos.
IL204437A (en) History of aryl cyclic profile and their use
TW200801003A (en) Novel compounds
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
CY1113573T1 (el) Selurampanel
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
ATE433447T1 (de) Pyrimiidinverbindungen
CY1109655T1 (el) Συνδεση των παραγωγων κινουκλιδινης στους μουσκαρινικους υποδοχεις μ3
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
SE0200920D0 (sv) Novel compounds